SCHEMBL641441

SCHEMBL641441

CCOP(=O)(OCC)c1ccccc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 2/20 0.44
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 4/20 0.42
KCNH2 Q12809 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
HSD17B10 Q99714 2/20 0.41
ACHE P22303 1/20 0.40
NR1I2 O75469 1/20 0.39
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18486629 0.86 MEN1 (0.61) MEN1KMT2APOLBNPSR1ALDH1A1
SCHEMBL28672462 0.84 MEN1 (0.49) MEN1KMT2APOLBNPSR1ALDH1A1
SCHEMBL10960177 0.83 NPSR1 (0.42) MEN1KMT2APOLBNPSR1ALDH1A1
SCHEMBL10960102 0.81 AOX1 (0.41) MEN1KMT2APOLBNPSR1ALDH1A1
SCHEMBL30987386 0.79 MEN1 (0.44) MEN1KMT2APOLBNPSR1ALDH1A1
SCHEMBL18486707 0.79 KMT2A (0.50) MEN1KMT2ANPSR1ALDH1A1KCNH2
SCHEMBL3890445 0.78 KMT2A (0.54) MEN1KMT2APOLBNPSR1ALDH1A1
SCHEMBL31482562 0.78 KMT2A (0.54) MEN1KMT2APOLBNPSR1ALDH1A1
SCHEMBL4455340 0.78 MEN1 (0.54) MEN1KMT2APOLBNPSR1ALDH1A1
SCHEMBL1629451 0.78 POLB (0.45) MEN1KMT2APOLBNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4444714-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) 2024-10-16 EP disclosed
CN-118742545-A Fused heterocyclic compounds as PI3K alpha inhibitors 南京征祥医药有限公司 2024-10-01 CN disclosed
WO-2023104111-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) 2023-06-15 WO disclosed
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
US-10103401-B2 Polymer electrolyte composition and polymer electrolyte membrane, polymer electrolyte membrane with catalyst layer, membrane electrode assembly, and polymer electrolyte fuel cell each using the same TORAY INDUSTRIES, INC. (JP) 2018-10-16 US disclosed
EP-3131145-B1 POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME TORAY INDUSTRIES (JP) 2018-09-05 EP disclosed
US-20170125832-A1 POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL EACH USING THE SAME TORAY INDUSTRIES, INC. (JP) 2017-05-04 US disclosed
EP-3131145-A1 POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME Toray Industries, Inc. (JP) 2017-02-15 EP disclosed
US-9550861-B2 Method for producing polyaniline having self-doping function and antistatic agent containing polyaniline produced thereby OSAKA UNIVERSITY (JP) 2017-01-24 US disclosed
CN-1063182-C New aminophenylphosphonic acid compounds, process for preparing them and pharmaceutical compositions containing them ADIR (FR) 2001-03-14 CN disclosed
US-6117873-A CAN BE USED FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS WHICH RESPOND TO BLOCKAGE OF EXCITATORY AMINO ACID RECEPTORS NOVARTIS AG (CH) 2000-09-12 US disclosed
CN-1234037-A Subsd. aminoalkane phosphonic acids NOVARTIS AG (CH) 1999-11-03 CN disclosed
EP-0934326-A1 SUBSTITUTED AMINOALKANE PHOSPHONIC ACIDS Novartis AG (CH) 1999-08-11 EP disclosed
WO-1998017672-A1 SUBSTITUTED AMINOALKANE PHOSPHONIC ACIDS NOVARTIS AG (CH) 1998-04-30 WO disclosed
US-5670493-A ANGIOGENESIS INHIBITORS ADIR ET COMPAGNIE (FR) 1997-09-23 US disclosed
CN-1145908-A New aminophenylphosphonic acid compounds, process for preparing them and pharmaceutical compositions containing them ADIR (FR) 1997-03-26 CN disclosed
US-4456668-A DYE BLEACH, TEXTILE DYES CIBA GEIGY AG (CH) 1984-06-26 US disclosed
US-4409143-A TEXTILES, PHOTOGRAPHY CIBA-GEIGY AG (CH) 1983-10-11 US disclosed
US-4379819-A OIL SOLUBLE MONOAZO DYE CIBA-GEIGY AG (CH) 1983-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 MEN1 782/4885KMT2A 2892/4885POLB 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.